BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 28

Sarepta Therapeutics Inc

SRPTNASDAQ
Trade with Public
Trade with Public
$18.64
-0.03-0.16%
마지막 업데이트: Sep 28, 9:29 AM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Sarepta Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sarepta Therapeutics (SRPT).

Price Target Range — 6 Quarters

Analyst Consensus — 24 Analysts

9Buy
10Hold
5Sell
Consensus RatingOutperform# Analysts24Avg. Consensus PT$25Upside to Avg. PT+33.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 28, 2026NeedhamGil BlumMaintainedUnderperform—
Jul 9, 2026Piper SandlerBiren AminPT CutNeutral$23→$20
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Underperform.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target

Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved